Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks

M I Aguilar, R Hart, M I Aguilar, R Hart

Abstract

Background: Non-valvular atrial fibrillation (AF) is associated with an increased risk of stroke mediated by embolism of stasis-precipitated thrombi from the left atrial appendage.

Objectives: The objective is to characterize the efficacy and safety of oral anticoagulants (OACs) for the primary prevention of stroke in patients with chronic AF.

Search strategy: We searched the Cochrane Stroke Group Trials Register (last searched in June 2004). In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 4, 2004), MEDLINE (1966 to June 2004), and the reference lists of recent review articles. We also contacted the Atrial Fibrillation Collaboration and experts working in the field to identify unpublished and ongoing trials.

Selection criteria: All randomized controlled trials comparing OACs with control in patients with chronic non-valvular atrial fibrillation and no history of transient ischemic attack (TIA) or stroke.

Data collection and analysis: Trials for inclusion were independently selected by two authors who also extracted each outcome and double-checked the data. The Peto method was used for combining odds ratios. All analysis were, as far as possible, intention-to-treat. Since the published results of four trials included 3% to 8% of participants with prior stroke or TIA, unpublished results excluding these participants were obtained from the Atrial Fibrillation Investigators.

Main results: Of 2313 participants without prior cerebral ischemia from five randomized trials, the mean age was 69 years. Participant features and study quality were similar between trials: the OAC in all five trials was warfarin. About half of participants (n = 1154) were randomized to adjusted-dose warfarin with mean achieved INRs ranging between 2.0 to 2.6. During 1.5 years mean follow up, warfarin was associated with large, highly statistically significant reductions in all strokes (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.26 to 0.59), ischemic stroke (OR 0.34, 95% CI 0.23 to 0.52), all disabling or fatal stroke (OR 0.47, 95% CI 0.28 to 0.80), death (OR 0.69, 95% CI 0.50 to 0.94) and the combined endpoint of all stroke, myocardial infarction or vascular death (OR 0.56, 95% CI 0.42 to 0.76). The observed rates of intracranial and extracranial hemorrhage were not significantly increased by OAC therapy, but the confidence intervals were wide.

Authors' conclusions: Treatment with adjusted-dose warfarin to achieved INRs of 2 to 3 reduces stroke, disabling or fatal stroke, and death for patients with non-valvular AF. The benefits were not substantially offset by increased bleeding among these participants in randomized clinical trials. Limitations include relatively short follow up and imprecise estimates of bleeding risks from the selected participants enrolled in the trials. For primary prevention of stroke in AF patients, about 25 strokes and about 12 disabling or fatal strokes would be prevented yearly for every 1000 atrial fibrillation patients given OACs.

Conflict of interest statement

Dr. Hart was a principal investigator of the SPAF I trial that is included in this review.

References

References to studies included in this review AFASAK I {published data only}

    1. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo‐controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175‐9.
BAATAF {published data only}
    1. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low‐dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. New England Journal of Medicine 1990;323:1505‐11.
CAFA {published data only}
    1. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. Journal of the American College of Cardiology 1991;18:349‐55.
SPAF I {published data only}
    1. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation 1991;84:527‐39.
SPINAF {published data only}
    1. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. New England Journal of Medicine 1992;327:1406‐12.
References to studies excluded from this review AFASAK II {published data only}
    1. Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, et al. Mini‐dose warfarin and aspirin in atrial fibrillation. Second Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation Study (AFASAK 2). Archives of Internal Medicine 1998;158:1513‐21.
EAFT {published data only}
    1. European Atrial Fibrillation Trial Study Group. Secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and recent transient ischemic attack or minor ischemic stroke. Lancet 1993;342:1255‐62.
Harenberg 1993 {published data only}
    1. Harenberg J, Weuster B, Pfitzei M, Dempfle CE, Stehle G, Kubler W, et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Seminars in Thrombosis and Hemostasis 1993;19 (Suppl):116‐21.
PATAF {published data only}
    1. Hellemons BSP, Langenberg M, Lodder J, Vermeer F, Schouten HJA, Ree JW, et al. Primary prevention of arterial thromboembolism in patients with nonrheumatic atrial fibrillation in general practice (the PATAF study). Cerebrovascular Diseases 1997;7 (Suppl 4):11.
Pengo 1998 {published data only}
    1. Pengo V, Zasso A, Barbero F, Banzato A, Nante G, Parissenti L, et al. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. American Journal of Cardiology 1998;82:433‐7.
SAFT {published data only}
    1. Edvardsson N, Juul‐Moller S, Omblus R, Pehrsson K. Effects of low‐dose warfarin and aspirin versus no treatment on stroke in a medium‐risk patient population with atrial fibrillation. Journal of Internal Medicine 2003;254:95‐101.
SPAF II {published data only}
    1. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687‐91.
SPAF III {published data only}
    1. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted‐dose warfarin versus low‐intensity, fixed‐dose warfarin plus aspirin for high‐risk patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;348:633‐8.
TAFT {published data only}
    1. Yigit Z. The Turkish atrial fibrillation study. Turk Kardiyoloji Dernegi Arsivi 2000;28:8‐19.
Additional references AFI 1994
    1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized clinical trials. Archives of Internal Medicine 1994;154:1949‐57.
Chimowitz 2005
    1. Chimowitz MI, Lynn MJ, Howlett‐Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. New England Journal of Medicine 2005;352(13):1305‐16.
Deeks 2001
    1. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care. Meta‐analysis in Context. London: BMJ Books, 2001:285‐312.
Feinberg 1995
    1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal RA, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Archives of Internal Medicine 1995;155:469‐73.
Gage 2001
    1. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285(22):2864‐70.
Go 2001
    1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285(18):2370‐5.
Go 2003
    1. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice. JAMA 2003;290(20):2685‐92.
Hart 1998
    1. Hart RG, Sherman DG, Easton JD, Cairns JA. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998;51:674‐81.
Hart 1999
    1. Hart RG, Pearce LA, McBride R, Rothbart R, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I‐III clinical trials. Stroke 1999;30(6):1223‐9.
Hart 2004
    1. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Annals of Internal Medicine 2003;138(10):831‐8.
Hylek 2003
    1. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. New England Journal of Medicine 2003;349(11):1019‐26.
Koudstaal 1995
    1. Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews 1999, Issue 3. [Art. No.: CD000185. DOI: 10.1002/14651858.CD000185]
Laupacis 1998
    1. Laupacis A, Albers GW, Dalen JE, Dunn MI, Jacobsen AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 1998;114 (5 Suppl):579S‐589S.
Oden 2005
    1. Oden A, Fahlen M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation. A critical appraisal. Thrombosis Research 2005 (in press).
SPAF 1998
    1. Stroke Prevention in Atrial Fibrillation Investigators. Prospective identification of patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin. JAMA 1998;279:1273‐7.
van Walraven 2002
    1. Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta‐analysis. JAMA 2002;288(19):2441‐8.
Wang 2003
    1. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, et al. A risk score for predicting stroke or death in individuals with new‐onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290(8):1049‐56.
Wolf 1991
    1. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983‐8.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever